Twenty meetings, warm feedback, no term sheet. The problem is rarely your numbers. It is the one belief the deck never moves.
Book a Strategy CallMost founders come to us after a round has gone quiet. Not rejected. Quiet.
The instinct is to read that as a volume problem, so they take thirty more meetings. Occasionally that works. Usually it produces thirty more versions of the same sentence.
Here's what's actually happening. Every investor has one thing they need to believe before they'll write a cheque, and in medtech it's almost never whether the device works. Your clinical data settled that before the meeting started.
What they're deciding is whether the market you describe will exist at all. And whether you're the company that ends up owning it.
Most medtech decks argue the technology beautifully and leave that question to inference. So the room never reaches it, and nobody tells you, because "interesting, but" is easier to say.
The one belief, identified. The specific thing a target investor has to accept before they invest, and the exact point in your current story where they stop accepting it.
A narrative built on the category. Investors and acquirers pay a premium for a position and a discount for a device. Most medtech decks are written as devices.
The deck rewritten. Structure, sequence and language, built to move that one belief. You sit in the working session that shapes it, and you approve every version.
The answers prepared. The four or five questions that have derailed your meetings, answered so the topic closes rather than opens.
The room narrowed. Targeting that takes a summit list of 250 down to the funds whose thesis genuinely fits.
A software investor can underwrite a pivot. Your regulator doesn't permit one.
That changes what your deck has to prove. You're asking somebody to fund a company that can't change direction, into a market that may not have formed, on a timeline set by a clearance pathway.
The narrative has to carry all three. So a generalist deck consultant will build you a beautiful software deck, and it'll lose in this room.
If you're pitching next week, we can work on the deck. But the narrative work needs longer, because it changes how investors describe you when you're not in the room.
Four to six weeks for the narrative and the deck. Kickoff, a working session, then drafting with your review at each stage.
Investor targeting runs alongside it and can be bought on its own.
Longer-horizon exit positioning is a separate retainer, because visibility to acquirers gets built over quarters.
If you'd rather see the problem yourself before you talk to anyone, run the deck through our Pitch Deck Analyzer. It reads your deck the way an investor in this space reads it, then reports back on where the argument breaks.
It's free, it takes a few minutes, and there's no call at the end of it. Plenty of founders run it, fix what it finds, and never speak to us. That's a fine outcome.
MarketCraft is a medtech market engineering agency, founded by Omar Khateeb. Omar sold surgical robots into hospitals before he built the firm, and he now speaks at the investor summits where medtech funds and strategics gather.
He also hosts State of MedTech, a podcast past 400 episodes with the founders, investors and operators in this industry. The investors you're trying to reach already listen to him. A deck consultant can't replicate that, and it tells us how these funds really decide.
The method isn't ours alone. MarketCraft is acknowledged in Market Engineering by Bruce Cleveland, published June 2026. Cleveland ran product and marketing at Apple and Oracle, then became a founding partner at Wildcat Venture Partners.
"MarketCraft joined the board of investors meeting, they were very impressed by MarketCraft's results."
Lloyd Mencinger, CEO, Aqua Medical
We write it. You shape it in the working session and you approve every version.
Good. Bankers run a process, and we make sure the company entering that process reads as a category leader.
Yes, and often more so. Pre-revenue companies get underwritten almost entirely on narrative.
Then we start there. An investor narrative built on an undefined category won't survive diligence, and that's a medtech branding problem.
We handle the narrative and the materials investors read first. Financial diligence stays with your CFO or your banker.
We'll read it with you and tell you which belief it fails to move. Thirty minutes, and you get the feedback whether or not we end up working together.
Or run it through the Pitch Deck Analyzer first, for nothing, and bring what it says.
P.S. If a round has already stalled, the useful question isn't what you should have said. It's which belief the room never reached, and the analyzer answers that in a few minutes for nothing.